Search Videos and More
News
Dana-Farber Researchers Explore AI's Potential Roles in Predicting and Diagnosing Cancer
In 2022 and 2023, you couldn't go a day without hearing about artificial intelligence (AI). Generative AI tools such as chatbots and art generators had become a central topic in everyday conversations. But AI in cancer has deeper roots. Twenty-five years before ChatGPT burst onto the scene, computers started playing a larger role in cancer diagnostics. In 1997, mammograms weren't even digital yet, but computers had started analyzing them. The tools, called expert systems, used hard-coded logic to read digital images of X-ray-based mammograms to look for signs of cancer.
Document
Treatment Guideline: Use of Low-Dose Tamoxifen in Patients with Estrogen Receptor-Positive (ER+) Ductal Carcinoma in Situ (DCIS)
The Breast Oncology Center at Dana-Farber Brigham Cancer Center developed expert-based consensus recommendations for the use of low-dose tamoxifen in patients with Ductal Carcinoma in Situ (DCIS).
News
Ancient DNA Reveals Origin of Racial/Ethnic Disparity in a Childhood Cancer
There are 40% more Hispanic/Latino kids diagnosed with acute lymphoblastic leukemia (ALL) than white non-Hispanic/Latino children; actually, Hispanic/Latino individuals have the highest risk of ALL in the United States. However, the basis for this difference is not well understood. Researchers recently identified a genetic variant that accounts for the increased risk of B-cell ALL in Hispanic/Latino children, and using ancient DNA, they traced the mutation all the way back to the first migrants who entered the Americas ~13,000 years ago.
News
Breast Cancer Trial Aims to Improve Treatment for Men
Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
News
Fox Chase Cancer Center Recognizes Nobel Laureate Dr. William Kaelin With the Stanley P. Reimann Honor Award
William Kaelin Jr., MD, physician, scientist, and Nobel laureate, was recognized today at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction. The award was presented to Kaelin while he was visiting Fox Chase to deliver a scheduled lecture.
News
Dana-Farber Cancer Institute Launches Neuro-Inclusive Oncology Care and Empowerment Program
Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).
News
Gordon J. Freeman, PhD, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR).
News
Palliative Care Leader Receives Prestigious ASCO Special Award
News
Bispecific Antibody Therapies for Lymphoma
Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own.
News
Dana-Farber Research Publication 03.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
Video
Testicular Cancer Conference Highlights from ASCO GU 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the testicular cancer clinical updates you need to know from ASCO GU 2024.